"I don’t mean to be presumptuous, but I liken myself to the robber barons.” So says Martin Shkreli, the 32-year-old hedge-fund manager turned pharmaceutical-company C.E.O., who achieved instantaneous notoriety last fall when he acquired the U.S. rights to a lifesaving drug and promptly boosted its price over 5,000 percent, from $13.50 a tablet to $750. The tsunami of rage (the BBC asked if Shkreli was “the most hated man in America”) only got worse when Shkreli said he would lower the price—and then didn’t. An anonymous user on the Web site Reddit summed up the sentiment bluntly: “Just fucking die will you?” “The attempt to public shame is interesting,” says Shkreli. “Because everything we’ve done is legal. [Standard Oil tycoon John D.] Rockefeller made no attempt to apologize as long as what he was doing was legal.” In fact, Shkreli says, he wishes he had raised the price higher. “My investors expect me to maximize profits,” he said in an interview in early December at the Forbes Healthcare Summit, after which Forbes contributor Dan Diamond summed up Shkreli as “fascinating, horrifying, and utterly compelling.”"
Issues and developments related to IP, AI, and OM, examined in the IP and tech ethics graduate courses I teach at the University of Pittsburgh School of Computing and Information. My Bloomsbury book "Ethics, Information, and Technology", coming in Summer 2025, includes major chapters on IP, AI, OM, and other emerging technologies (IoT, drones, robots, autonomous vehicles, VR/AR). Kip Currier, PhD, JD
Showing posts with label acquiring patent rights to lifesaving drug and boosting price. Show all posts
Showing posts with label acquiring patent rights to lifesaving drug and boosting price. Show all posts
Sunday, December 20, 2015
Everything You Know About Martin Shkreli Is Wrong—or Is It?; Vanity Fair, 1/31/16
Bethany Mclean, Vanity Fair; Everything You Know About Martin Shkreli Is Wrong—or Is It? :
Subscribe to:
Posts (Atom)